Seibert G, Isert D, Klesel N, Limbert M, Markus A, Schrinner E
Hoechst AG, SBU Anti-infectives Research, Frankfurt, Germany.
J Antimicrob Chemother. 1992 Apr;29 Suppl A:25-30. doi: 10.1093/jac/29.suppl_a.25.
Cefpirome, cefoperazone and ceftazidime were tested for their in-vitro activity against Enterococcus faecalis and methicillin-resistant Staphylococcus aureus (MRSA) isolates. Cefpirome was the most active cephalosporin followed by cefoperazone. Ceftazidime had only very limited activity against these strains. In experiments with cefpirome/vancomycin and cefoperazone/vancomycin combinations, synergy was detected against most MRSA strains and some enterococci. Antagonism did not occur.
对头孢匹罗、头孢哌酮和头孢他啶进行了体外活性测试，以检测其对粪肠球菌和耐甲氧西林金黄色葡萄球菌（MRSA）分离株的活性。头孢匹罗是活性最强的头孢菌素，其次是头孢哌酮。头孢他啶对这些菌株的活性非常有限。在头孢匹罗/万古霉素和头孢哌酮/万古霉素联合用药的实验中，检测到对大多数MRSA菌株和一些肠球菌有协同作用。未出现拮抗作用。
